Anti-PD-1/PD-L1 Therapy associated Colitis is associated with Upregulation of Tight Junction Claudin-2
Chicago EYES on Cancer is funded by a grant to the University of Chicago Medicine Comprehensive Cancer Center from the National Cancer Institute (#R25 CA221767) and philanthropic support.
Abstract
Anti-PD-1/PD-L1 therapy is an immunotherapy used to treat cancer. Patients can experience severe colitis and diarrhea as a result of this medication. We performed immunohistochemical staining on 20 colon biopsies from patients experiencing colitis from anti-PD-1/PD-L1 therapy and compared them to healthy aged matched controls. Our results showed that expression of claudin-2 in intestinal crypts was significantly higher in patients with anti-PD-1/PD-L1 colitis, which may contribute to increased paracellular water flux and diarrhea in these patients.
This paper has been withdrawn.
